RxDoctor Payments Data

Briana Disilvio, MD

Critical Care Medicine · Pittsburgh, PANPI 1134569973

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $186,765 of the $203,545 with a category attached, or 91.8%. 17 manufacturers reported payments, led by Boehringer Ingelheim at 57.0% of the total. 2025 is the largest year on record at $95,922, more than ten times the $564 reported in 2019. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$203,545in general payments, 2019–2025

Across 224 payments — averaging $908.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$116K
  • GSK$31K
  • AstraZeneca$29K
  • Verona Pharma, Inc.$26K
  • Regeneron Healthcare Solutions, Inc.$253
  • Pulmonx Corporation$239
  • plus $985 from 11 others
$222,459in research payments, 2019–2025

Across 132 payments — averaging $1685.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$211K
  • Boehringer Ingelheim International GmbH$11K

What the payments were for

  • Consulting fees$1,9501%
  • Speaking & faculty fees$186,76592%
  • Travel & lodging$4,6292%
  • Food & beverage$9,9075%
  • Education$2940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$203,545 in reported general payments places this provider in the 95th percentile of 354 critical care medicine providers in Pennsylvania.

See all critical care medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$69,557
Medicare patients
273
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate36$464,463
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$78,122
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr75$40,785
Breztri AerosphereBudesonide/Glycopyr/Formoterol54$39,429
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate83$13,581
Breo ElliptaFluticasone/Vilanterol26$10,322
DuleraMometasone/Formoterol23$7,750
Spiriva RespimatTiotropium Bromide13$6,828
Combivent RespimatIpratropium/Albuterol Sulfate14$6,434
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$5,717
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$5,281
Fluticasone Propionate HfaFluticasone Propionate14$3,719
SymbicortBudesonide/Formoterol Fumarate16$3,613
Albuterol Sulfate HfaAlbuterol Sulfate113$2,688
BreynaBudesonide/Formoterol Fumarate11$2,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$115,992$483,44276 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$30,756$129,230214 claims
AstraZenecaBreztri Aerosphere, Symbicort$29,364$43,04270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 critical care medicine providers in Pennsylvania.

Other critical care medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →